for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Chembio Diagnostics Inc

CEMI.OQ

Latest Trade

5.54USD

Change

0.01(+0.18%)

Volume

4,364

Today's Range

5.52

 - 

5.63

52 Week Range

4.51

 - 

10.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.53
Open
5.59
Volume
4,364
3M AVG Volume
0.96
Today's High
5.63
Today's Low
5.52
52 Week High
10.20
52 Week Low
4.51
Shares Out (MIL)
17.57
Market Cap (MIL)
97.49
Forward P/E
-8.35
Dividend (Yield %)
--

Latest Developments

More

Chembio Diagnostics Reports Q2 2019 Results

Chembio Diagnostics Q1 Loss Per Share $0.16 Including Items

Chembio Diagnostics Announces Approval of Zika, Dengue and Chikungunya Point-of-Care Multiplex Test by Brazil’s Health Regulatory Agency

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Chembio Diagnostics Inc

Chembio Diagnostics, Inc. (Chembio), and its subsidiary, Chembio Diagnostic Systems, Inc., develop, manufacture, market and license rapid point-of-care diagnostic tests (POCTs) that detect infectious diseases. The Company's products available are rapid tests for the detection of human immunodeficiency virus (HIV) 1/2 antibodies, and a multiplex rapid test for the detection of HIV and Syphilis antibodies. The HIV 1/2 rapid tests employ in-licensed and lateral flow technologies that are used with all blood matrices as samples, and are manufactured in a standard cassette format, a dipstick format and a barrel format. Its HIV 1/2 rapid antibody detection test incorporates the Dual Path Platform (DPP) POCT technology. The DPP HIV 1/2 Assay detects antibodies to HIV 1 and 2 in oral fluid samples, as well as in all blood matrices. The Company's product pipeline includes a multiplex rapid test for earlier detection of HIV and a multiplex test that detects HIV and Syphilis specific antibodies.

Industry

Biotechnology & Drugs

Contact Info

555 Wireless Blvd

+1.631.9241135

http://chembio.com/

Executive Leadership

Katherine Lyon Davis

Non-Executive Independent Chairman of the Board

John J. Sperzel

President, Chief Executive Officer, Director

Neil A. Goldman

Chief Financial Officer, Executive Vice President

Javan Esfandiari

Chief Science and Technology Officer

Tom Ippolito

Vice President - Regulatory Affairs, Quality Assurance and Quality Control

Key Stats

1.50 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.260

2017

-0.520

2018

-0.550

2019(E)

-0.665
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.80
Price To Book (MRQ)
3.49
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
1.87
LT Debt To Equity (MRQ)
0.96
Return on Investment (TTM)
-39.37
Return on Equity (TTM)
-32.13

Latest News

Latest News

BRIEF-Chembio Diagnostics Reports Q1 Loss Per Share $0.05

* CHEMBIO DIAGNOSTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Chembio Diagnostics And Lumiradx Enter Collaboration To Develop New Point-Of-Care Diagnostic Tests For Infectious Diseases

* CHEMBIO DIAGNOSTICS AND LUMIRADX ENTER COLLABORATION TO DEVELOP NEW POINT-OF-CARE DIAGNOSTIC TESTS FOR INFECTIOUS DISEASES

BRIEF-Chembio Diagnostics Q4 Loss Per Share $0.16

* CHEMBIO DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Chembio Diagnostics Announces Proposed Public Offering Of Common Stock

* CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Chembio Diagnostics Announces Major New Tender Win And Certain Preliminary 2017 Financial Results

* CHEMBIO DIAGNOSTICS ANNOUNCES MAJOR NEW TENDER WIN AND CERTAIN PRELIMINARY 2017 FINANCIAL RESULTS

BRIEF-Chembio Diagnostics Appoints Neil Goldman As CFO

* CHEMBIO DIAGNOSTICS ANNOUNCES APPOINTMENT OF NEIL A. GOLDMAN AS CHIEF FINANCIAL OFFICER

BRIEF-Chembio Diagnostics And Astrazeneca Collaborates To Develop Point-Of-Care Diagnostic Test

* CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST

BRIEF-Chembio receives $8.5 mln commitment from Bio-Manguinhos to purchase components for production of dpp Assays in Brazil during 2018

* CHEMBIO RECEIVES $8.5 MILLION COMMITMENT FROM BIO-MANGUINHOS TO PURCHASE COMPONENTS FOR PRODUCTION OF DPP® ASSAYS IN BRAZIL DURING 2018

BRIEF-Chembio Diagnostics Awarded UNICEF Contract

* CHEMBIO DIAGNOSTICS AWARDED UNICEF CONTRACT TO SUPPLY POINT-OF-CARE DPP® ZIKA ASSAYS AND DPP® MICRO READERS

BRIEF-Chembio Diagnostics posts Q3 loss of $0.05 per share

* Chembio diagnostics reports third quarter 2017 financial results

BRIEF-Chembio Diagnostics CEO has returned to work after a medical leave of absence​

* Chembio Diagnostics Inc - president and CEO John Sperzel has returned to work following a medical leave of absence Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test

* Chembio Diagnostics receives FDA emergency use authorization for the first rapid Zika Igm test Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Chembio Diagnostics reports Q2 loss per share of $0.18

* Chembio Diagnostics reports second quarter 2017 financial results

BRIEF-Chembio Diagnostics Inc qtrly ‍net loss $0.18- SEC Filing

* Chembio Diagnostics Inc qtrly net loss of $2.17 million, or $0.18 per diluted share

BRIEF-Chembio's DPP Zika System including the DPP Micro Reader approved by Brazil's Health Regulatory Agency

* Chembio's DPP® zika system including the DPP® micro reader approved by Brazil's Health Regulatory Agency

BRIEF-Chembio diagnostics announces At-The-Market-Program

* Chembio Diagnostics- announced that it has established an "at--market" program through which it may offer and sell up to $21.2 million of common stock

BRIEF-Acuta Capital Partners reports a 10.3 pct passive stake in Chembio Diagnostics

* Acuta Capital Partners LLC reports a 10.3 percent passive stake in Chembio Diagnostics Inc as of May 31, 2017 - SEC filing Source text for Eikon: (http://bit.ly/2s26Att) Further company coverage:

BRIEF-Chembio Diagnostics reports Q1 loss per share $0.13

* Chembio Diagnostics reports first quarter 2017 financial results

BRIEF-Chembio and Find collaborate to develop point-of-care multiplex test

* Chembio and Find collaborate to develop point-of-care multiplex test for acute febrile illnesses in asia pacific Source text for Eikon: Further company coverage:

BRIEF-Chembio Diagnostics Q4 loss per share $0.21

* Q4 revenue fell 3.8 percent to $4.25 million Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up